As the PD-1/PD-L1 axis is a major immune checkpoint that confers adaptive immune resistance in various tumor contexts (25, 31, 32), we have employed CD8 and PD-L1 as surrogate markers of the anti-tumor immune response. This evidence concerns the gene CD8A and neoplasm.